TREE NEWS update: Chongqing Chen’an Biopharmaceutical, a controlling subsidiary of Zhifei Biological, has received acceptance notices (CXSS2600146, CXSS2600147) from China’s National Medical Products Administration for its self-developed biosimilar semaglutide injection. The product is intended for glycemic control in adults with type 2 diabetes.
Zhifei’s Semaglutide Injection Gets NMPA Filing Acceptance for Type 2 Diabetes
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
10m ago
Nanda Environment’s top shareholder to sell at least 15% stake
11m ago
Benchuan Smart plans up to 1B yuan high-end PCB project
12m ago
BenChuan Smart plans ~$280M AI PCB plant in Nanjing
12m ago
Zhuhai Mian Group: Kangge Investment to acquire 96.28% stake in Haicheng
17m ago
Boston Scientific Warns Cyberattack to Hit Earnings Outlook
25m ago
Meituan Flash Sales to Debut Apple, Huawei, Xiaomi Foldables